Patents by Inventor Areum BAEK

Areum BAEK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORM OF LIFITEGRAST, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    Publication number: 20230382897
    Abstract: Provided is a novel crystalline form of lifitegrast and a pharmaceutical composition containing the novel crystalline form of lifitegrast. The crystalline form of lifitegrast has improved solubility and excellent stability against heat and moisture, thereby being effectively used for preparing a pharmaceutical composition.
    Type: Application
    Filed: October 14, 2021
    Publication date: November 30, 2023
    Applicant: YS LIFE SCIENCE CO. LTD.
    Inventors: Eunim JEONG, Areum BAEK, Hyunik SHIN
  • CRYSTALLINE SALT OF ERIBULIN
    Publication number: 20230234961
    Abstract: An eribulin salt formed by combining an eribulin free base with a low molecular weight amine compound through a diacid compound is disclosed. As the diacid compound, edisylic acid, 1,5-naphthalenedisulfonic acid, trans-2-butene-1,4-dicarboxylic acid, pyrophosphoric acid, and combination thereof may be employed. As the amine, ammonia, cyclohexylamine, dicyclohexylamine, and a combination thereof may be employed. The eribulin salt can be crystallized by recrystallization to produce a crystalline eribulin salt with increased purity.
    Type: Application
    Filed: May 6, 2021
    Publication date: July 27, 2023
    Applicant: YONSUNG FINE CHEMICAL CO., LTD.
    Inventors: Areum BAEK, Hyunik SHIN, Yongseo PARK, Seongtaek KIM, Seunghui SIN
  • PRODUCTION METHOD FOR INDUCED DOPAMINERGIC NEURONAL PROGENITORS, USING DIRECT REPROGRAMMING
    Publication number: 20230000923
    Abstract: The present invention relates to a method for producing induced dopaminergic neuronal progenitors from adult cells using direct reprogramming, induced dopaminergic neuronal progenitors produced via the method and a use for same, wherein, as a result of having been directly reprogrammed from adult cells, the induced dopaminergic neuronal progenitors produced by means of the present invention can be transplanted inside a living body without the risk of oncogenicity, and have excellent proliferative capacity and dopaminergic neuronal differentiation potency, thus can be usefully utilized as a cell therapy product for Parkinson's disease.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 5, 2023
    Inventors: Janghwan KIM, Minhyung LEE, Mi Young SON, Young Joo JEON, Areum BAEK, Young Jeon LEE, Jincheol SEO, Cho Rok JUNG
  • Ophthalmic composition for glaucoma treatment
    Patent number: 11382887
    Abstract: An eye drop composition for treating glaucoma is disclosed. The eye drop composition includes a prostaglandin analogue, a thickening agent, and a solubilizing agent, wherein the thickening agent is carboxymethylcellulose or a salt thereof, and the solubilizing agent is tyloxapol.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: July 12, 2022
    Assignee: YS LIFE SCIENCE CO. LTD.
    Inventors: Areum Baek, Youngsik Chung, Hyun Ik Shin, Chang Young Oh, Kee Young Lee
  • OPHTHALMIC COMPOSITION FOR GLAUCOMA TREATMENT
    Publication number: 20200129468
    Abstract: An eye drop composition for treating glaucoma is disclosed. The eye drop composition includes a prostaglandin analogue, a thickening agent, and a solubilizing agent, wherein the thickening agent is carboxymethylcellulose or a salt thereof, and the solubilizing agent is tyloxapol.
    Type: Application
    Filed: June 21, 2018
    Publication date: April 30, 2020
    Applicant: YONSUNG FINE CHEMICAL CO., LTD.
    Inventors: Areum BAEK, Youngsik CHUNG, Hyun Ik SHIN, Chang Young OH, Kee Young LEE